Holen Sie sich die Stockscreener-App
6.1982
1.15%
-0.0718
Vorhandelsmarkt:
6.21
0.0118
+0.19%
Schlusskurs vom Vortag:
$6.27
Offen:
$6.34
24-Stunden-Volumen:
10,844
Relative Volume:
0.70
Marktkapitalisierung:
$44.37M
Einnahmen:
$71,000
Nettoeinkommen (Verlust:
$-2.47M
KGV:
-0.1883
EPS:
-32.9143
Netto-Cashflow:
$-5.24M
1W Leistung:
-3.00%
1M Leistung:
-30.51%
6M Leistung:
-43.99%
1J Leistung:
-66.43%
1-Tages-Spanne:
$6.19
$6.34
1-Wochen-Bereich:
$6.025
$6.37
52-Wochen-Spanne:
$6.00
$28.44
Pavmed Inc Stock (PAVM) Company Profile
Firmenname
Pavmed Inc
Sektor
Branche
Telefon
(212) 949-4319
Adresse
360 MADISON AVENUE, NEW YORK, NY
Compare PAVM vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PAVM
Pavmed Inc
|
6.1982 | 44.89M | 71,000 | -2.47M | -5.24M | -32.91 |
ABT
Abbott Laboratories
|
85.60 | 150.32B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
305.09 | 117.93B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
73.81 | 97.02B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
48.31 | 72.99B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.47 | 49.50B | 6.30B | 1.07B | 1.09B | 1.8406 |
Pavmed Inc Stock (PAVM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-03-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-11-05 | Eingeleitet | Ascendiant Capital Markets | Buy |
| 2018-06-28 | Eingeleitet | Maxim Group | Buy |
Pavmed Inc Aktie (PAVM) Neueste Nachrichten
PAVM assigns Joseph Virgilio to lead medical device portfolio relaunch - MSN
PAVmed Q1 2026 earnings preview - MSN
PAVM Technical Analysis | Trend, Signals & Chart Patterns | PAVMED INC (NASDAQ:PAVM) - ChartMill
LUCD - Finviz
PAVM Technical Analysis & Stock Price Forecast - Intellectia AI
PAVmed Inc. (PAVM) reports Q1 loss, lags revenue estimates - MSN
PAVM PE Ratio & Valuation, Is PAVM Overvalued - Intellectia AI
Will PAVmed Inc. (PAVM) report negative earnings next week? What you should know - MSN
PAVM|PAVmed Inc|Price:6.390|Chg%:0.04 - TradingKey
Earnings call transcript: PAVmed Q1 2026 sees restructuring gains - Investing.com India
Earnings call transcript: PAVmed Q1 2026 sees restructuring gains By Investing.com - Investing.com Australia
Maxim Group Maintains PAVmed(PAVM.US) With Buy Rating, Maintains Target Price $16 - Moomoo
PAVmed Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:PAVM) 2026-05-19 - Seeking Alpha
PAVmed Inc earnings dates,PAVmed Inc earnings estimates - RTTNews
Lucid Diagnostics Inc. (LUCD) reports Q1 loss, misses revenue estimates - MSN
PAVmed Inc. (NASDAQ:PAVM) Q1 2026 Earnings Call Transcript - Insider Monkey
PAVmed Inc (PAVM) Q1 2026 Earnings Call Highlights: Strategic Re - GuruFocus
PAVM Reports Strong Q1 Growth and Financial Position - GuruFocus
PAVmed Inc (PAVM) Q1 2026 Earnings Call Highlights: Strategic Restructuring and Growth ... By GuruFocus - Investing.com Canada
Two Seas Capital (NASDAQ: PAVM) Holds 9.99% of PAVmed, Including Warrants - Stock Titan
PAVM: Restructuring completed; subsidiaries near major milestones and capital structure is simplified - TradingView
PAVmed Inc.Common Stock (NQ: PAVM - FinancialContent
PAVmed (PAVM) Q1 2026 Earnings Transcript - AOL.com
PAVmed Releases Q1 2026 Financial Results - AlphaStreet
PAVmed targets Varis FDA submission by end of 2026 while evaluating new assets following cap table cleanup - MSN
PAVmed Q1 2026 Earnings Call Insights - Intellectia AI
PAVmed (PAVM) Q4 2025 Earnings Transcript - The Globe and Mail
PAVmed Reports Q1 2026 Financial Results, Highlights Progress in Veris Health FDA Submission and Lucid Diagnostics Commercial Expansion - Minichart
PAVmed Reports Wider-than-Expected Q1 2026 Loss - AlphaStreet
PAVmed Q1 2026 Earnings Call Transcript - Benzinga
PAVM: Restructuring complete; subsidiaries advancing, with growth tied to capital and milestone achievements - TradingView
Earnings call transcript: PAVmed Inc. Q1 2026 shows restructuring gains By Investing.com - Investing.com Australia
PAVM: Restructuring enables growth, with Lucid and Veris advancing toward major milestones - TradingView
Earnings call transcript: PAVmed Inc. Q1 2026 shows restructuring gains - Investing.com
PAVmed (PAVM) Q1 2026: EPS $(4.42) Misses $(0.70) Estimate; Reve - GuruFocus
PAVmed Inc. (PAVM) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
PAVmed Reports Q1 2026 Results and Business Update - TipRanks
Q1 2026 PAVmed Inc Earnings Call Transcript - GuruFocus
PAVmed (NASDAQ: PAVM) Q1 2026 results, losses and cash position - Stock Titan
PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results - PR Newswire
PAVmed (PAVM) upgraded to buy: Here's what you should know - MSN
PAVmed Inc reports results for the quarter ended March 31Earnings Summary - TradingView
PAVmed Reports Business Expansion and Financial Update - Intellectia AI
PAVM: Q1 2026 saw $1.3M revenue, improved adjusted loss, and a strengthened cash position into 2027 - TradingView
PAVmed (NASDAQ: PAVM) posts Q1 2026 loss and flags going concern risks - Stock Titan
Finanzdaten der Pavmed Inc-Aktie (PAVM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.59%
1.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):